Background and objective: Cabozantinib remains the cornerstone for treatment of patients metastatic renal cell carcinoma (mRCC), whether pretreated with an immune-oncology (IO) agent and/or tyrosine kinase inhibitor, or treatment... ...

请注册登录后继续浏览